Standout Papers
Citation Impact
Citing Papers
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
2005 Standout
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Role of viruses in etiology and pathogenesis of multiple sclerosis
2001
The Nrf2-Antioxidant Response Element Signaling Pathway and Its Activation by Oxidative Stress
2009 Standout
Expansive discovery of chemically diverse structured macrocyclic oligoamides
2024 StandoutScienceNobel
Engineering precision nanoparticles for drug delivery
2020 Standout
The development of Cop 1 (Copaxone®), and innovative drug for the treatment of multiple sclerosis: personal reflections
1996
Expression profiling identifies responder and non‐responder phenotypes to interferon‐β in multiple sclerosis
2003
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
2008
Pediatric multiple sclerosis
2009
Microglia: active sensor and versatile effector cells in the normal and pathologic brain
2007 Standout
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
2005 Standout
Interactions between the microbiota, immune and nervous systems in health and disease
2017 Standout
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
2006
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
2010 Standout
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
2012
Sjögren's syndrome
2005 Standout
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial
2007
Rheumatoid arthritis
2016 Standout
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
2009 StandoutNobel
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
2010 Standout
The Effect of Infections on Susceptibility to Autoimmune and Allergic Diseases
2002 Standout
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
Vitamin D and Multiple Sclerosis
1997
US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis
2005
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
2003
Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives
1997
Pediatric Multiple Sclerosis
2011
The cost burden of multiple sclerosis in the United States: a systematic review of the literature
2013
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
2013
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
2008 Standout
Cancer nanotechnology: opportunities and challenges
2005 Standout
Multiple sclerosis
2008 Standout
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
2008
In vivo cancer targeting and imaging with semiconductor quantum dots
2004 Standout
Lack of evidence for use of glatiramer acetate in multiple sclerosis
2004
Polymer conjugates as anticancer nanomedicines
2006 Standout
The origin and application of experimental autoimmune encephalomyelitis
2007
Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis
2010 Standout
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients
2007
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease
2005
Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
2012 Standout
Association between Helicobacter pylori infection and dementia
2014
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
2006 Standout
Axonal Transection in the Lesions of Multiple Sclerosis
1998 Standout
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
1998 Standout
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
2011 Standout
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
2010
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
2012 Standout
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
2006
Regular review: Drug treatment of multiple sclerosis
2000
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
2006
Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor
2003
Multiple Sclerosis
2000 Standout
In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis
2003
Intrathecal activation of the complement system and disability in multiple sclerosis
1998
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
2008
Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
2000
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Inflammasomes: mechanism of action, role in disease, and therapeutics
2015 Standout
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
2004 Standout
Head and Neck Cancer
2001 Standout
The dawning era of polymer therapeutics
2003 Standout
Trends in peptide drug discovery
2021
Multiple sclerosis
2002 Standout
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
2012
Recent progress in the diagnosis and treatment of multiple sclerosis
1999
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
2013
Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer
2000
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
1998 Standout
Assessing disability progression with the Multiple Sclerosis Functional Composite
2009
Multiple Sclerosis
2018 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
2008
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
2004 StandoutNobel
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
IMMUNOLOGY OF MULTIPLE SCLEROSIS
2005 Standout
Drug treatment of multiple sclerosis
2000
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Multiple sclerosis
2004
The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis
2018 Standout
Of Mice and Not Men: Differences between Mouse and Human Immunology
2004 Standout
Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis
2004
Fluorescent Chemosensors Based on Spiroring-Opening of Xanthenes and Related Derivatives
2011 Standout
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS
2007
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]
2002
Works of Benjamin Brooks being referenced
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
2000
In Vitro Effects of Cholesterol β-d-Glucoside, Cholesterol and Cycad Phytosterol Glucosides on Respiration and Reactive Oxygen Species Generation in Brain Mitochondria
2010
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
2000
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
1995 Standout
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
1998